Mostrar el registro sencillo del ítem

Next generation metronomic chemotherapy - report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6 - 8 May 2016, Mumbai

hal.structure.identifierAnticancer Fund [Strombeek-Bever, Belgium]
dc.contributor.authorPANTZIARKA, Pan
hal.structure.identifierNature Reviews Clinical Oncology [London, UK]
dc.contributor.authorHUTCHINSON, Lisa
hal.structure.identifierMetronomics Global Health Initiative
hal.structure.identifierService de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM]
hal.structure.identifierCentre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2]
dc.contributor.authorANDRÉ, Nicolas
hal.structure.identifierModélisation Mathématique pour l'Oncologie [MONC]
hal.structure.identifierInstitut de Mathématiques de Bordeaux [IMB]
dc.contributor.authorBENZEKRY, Sébastien
hal.structure.identifierEuropean Institute of Oncology [Milan] [ESMO]
dc.contributor.authorBERTOLINI, Francesco
hal.structure.identifierMalabar Cancer Center
dc.contributor.authorBHATTACHARJEE, Atanu
hal.structure.identifierTata Memorial Centre
dc.contributor.authorCHIPLUNKAR, Shubhada
hal.structure.identifierMassachusetts General Hospital [Boston]
dc.contributor.authorDUDA, Dan
hal.structure.identifierTata Memorial Centre
dc.contributor.authorGOTA, Vikram
hal.structure.identifierTata Memorial Centre
dc.contributor.authorGUPTA, Sudeep
hal.structure.identifierTata Memorial Centre
dc.contributor.authorJOSHI, Amit
hal.structure.identifierTata Memorial Centre
dc.contributor.authorKANNAN, Sadhana
hal.structure.identifierSunnybrook Research Institute [Toronto] [SRI]
dc.contributor.authorKERBEL, Robert
hal.structure.identifierDana-Farber Cancer Institute [Boston]
dc.contributor.authorKIERAN, Mark
hal.structure.identifierEuropean Institute of Oncology [Milan] [ESMO]
dc.contributor.authorPALAZZO, Antonella
hal.structure.identifierPRA Health sciences [Mumbai]
dc.contributor.authorPARIKH, Aparna
hal.structure.identifierCentre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2]
hal.structure.identifierMetronomics Global Health Initiative
dc.contributor.authorPASQUIER, Eddy
hal.structure.identifierTata Memorial Centre
dc.contributor.authorPATIL, Vijay
hal.structure.identifierTata Memorial Centre
dc.contributor.authorPRABHASH, Kumar
hal.structure.identifierTechnion - Israel Institute of Technology [Haifa]
dc.contributor.authorSHAKED, Yuval
hal.structure.identifierHelen DeVos Children’s Hospital [Grand Rapids, MI, USA]
dc.contributor.authorSHOLLER, Giselle
hal.structure.identifierMasaryk University [Brno] [MUNI]
dc.contributor.authorSTERBA, Jaroslav
hal.structure.identifierBoston University [Boston] [BU]
dc.contributor.authorWAXMAN, David
hal.structure.identifierMetronomics Global Health Initiative
hal.structure.identifierTata Memorial Centre
dc.contributor.authorBANAVALI, Shripad
dc.date.accessioned2024-04-04T03:13:11Z
dc.date.available2024-04-04T03:13:11Z
dc.date.issued2016
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/193934
dc.description.abstractEnThe 5th Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6th – 8th May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations. Drug repurposing was discussed both in terms of clinical results, particularly with respect to angiosarcoma and high-risk neuroblastoma, and in pre-clinical settings, particularly the potential for peri-operative interventions. However, it was clear that there remain a number of key areas of challenge, particularly in terms of definitions, perceptions in the wider oncological community, mechanisms of action and pre- dictive biomarkers. While the potential for metronomics and drug repurposing in low and middle income countries remains a key theme, it is clear that there is also considerable potential for clinically relevant improvements in patient outcomes even in high income economies.
dc.language.isoen
dc.publisherecancer Global Foundation
dc.subject.encancer
dc.subject.enanti-angiogenics
dc.subject.endrug repurposing
dc.subject.enLMIC
dc.subject.enmetronomic chemotherapy
dc.title.enNext generation metronomic chemotherapy - report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6 - 8 May 2016, Mumbai
dc.typeArticle de revue
dc.identifier.doi10.3332/ecancer.2016.689
dc.subject.halSciences du Vivant [q-bio]/Cancer
bordeaux.journalEcancermedicalscience
bordeaux.volume10
bordeaux.hal.laboratoriesInstitut de Mathématiques de Bordeaux (IMB) - UMR 5251*
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.institutionCNRS
bordeaux.peerReviewedoui
hal.identifierhal-01392473
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-01392473v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Ecancermedicalscience&rft.date=2016&rft.volume=10&rft.au=PANTZIARKA,%20Pan&HUTCHINSON,%20Lisa&ANDR%C3%89,%20Nicolas&BENZEKRY,%20S%C3%A9bastien&BERTOLINI,%20Francesco&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem